Hormones of adipose tissue and their biologic role in lung cancer

Cancer Treatment Reviews

Volumn 40, Issue 1, 2014, Pages 22-30

  Ntikoudi, E ^a   Kiagia, M ^a   Boura, P ^a   Syrigos, K N ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Adipocytokines; Adiponectin; Chemerin; Leptin; Lung cancer; Resistin; Visfatin

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; CHEMERIN; LEPTIN; LEPTIN RECEPTOR; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RESISTIN;

ADIPOSE TISSUE; CACHEXIA; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; INFLAMMATION; LUNG CANCER; LUNG CARCINOGENESIS; NUTRITIONAL STATUS; OBESITY; PATHOGENESIS; REVIEW;

ADIPOCYTOKINES; ADIPONECTIN; CHEMERIN; LEPTIN; LUNG CANCER; RESISTIN; VISFATIN;

ADIPOSE TISSUE; ANIMALS; CARCINOGENESIS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; OBESITY; PEPTIDE HORMONES; RISK;

EID: 84887109344     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.06.005     Document Type: Review

References (111)

1. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 1994, 372(6505):425-432.
2. Ahima R.S., Flier J.S. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000, 11(8):327-332.
3. Gelsinger C., Tschoner A., Kaser S., Ebenbichler C.F. Adipokine update - new molecules, new functions. Wien Med Wochenschr 2010, 160(15-16):377-390.
4. Meier U., Gressner A.M. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem 2004, 50(9):1511-1525.
5. Pannacciulli N., Vettor R., Milan G., et al. Anorexia nervosa is characterized by increased adiponectin plasma levels and reduced nonoxidative glucose metabolism. J Clin Endocrinol Metab 2003, 88(4):1748-1752.
6. Dahlman I., Mejhert N., Linder K., et al. Adipose tissue pathways involved in weight loss of cancer cachexia. Br J Cancer 2010, 102(10):1541-1548.
7. Chu S.H., Lee M.K., Ahn K.Y., et al. Chemerin and adiponectin contribute reciprocally to metabolic syndrome. PLoS One 2012, 7(4):e34710.
8. Matsuzawa Y. Establishment of a concept of visceral fat syndrome and discovery of adiponectin. Proc Jpn Acad Ser B Phys Biol Sci 2010, 86(2):131-141.
9. Bray G.A. The underlying basis for obesity: relationship to cancer. J Nutr 2002 Nov, 132(11 Suppl.):3451S-3455S.
10. Khandekar M.J., Cohen P., Spiegelman B.M. Molecular mechanisms of cancer development in obesity. Nat Rev Cancer 2011 Nov 24, 11(12):886-895.
11. Chen J. Multiple signal pathways in obesity-associated cancer. Obes Rev 2011 Dec, 12(12):1063-1070.
12. Housa D., Housová J., Vernerová Z., Haluzík M. Adipocytokines and cancer. Physiol Res 2006, 55(3):233-244.
13. Knekt P., Heliövaara M., Rissanen A., et al. Leanness and lung-cancer risk. Int J Cancer 1991, 49(2):208-213.
14. Drinkard C.R., Sellers T.A., Potter J.D., et al. Association of body mass index and body fat distribution with risk of lung cancer in older women. Am J Epidemiol 1995, 142(6):600-607.
15. Kanashiki M., Sairenchi T., Saito Y., Ishikawa H., Satoh H., Sekizawa K. Body mass index and lung cancer: a case-control study of subjects participating in a mass-screening program. Chest 2005, 128(3):1490-1496.
16. Leung C.C., Lam T.H., Yew W.W., Chan W.M., Law W.S., Tam C.M. Lower lung cancer mortality in obesity. Int J Epidemiol 2011 Feb, 40(1):174-182.
17. Yang R., Cheung M.C., Pedroso F.E., Byrne M.M., Koniaris L.G., Zimmers T.A. Obesity and weight loss at presentation of lung cancer are associated with opposite effects on survival. J Surg Res 2011, 170(1):e75-e83. Epub 2011 May 23.
18. Muoio D.M., Lynis Dohm G. Peripheral metabolic actions of leptin. Best Pract Res Clin Endocrinol Metab 2002, 16(4):653-666.
19. Thomas T., Burguera B., Melton L.J., et al. Relationship of serum leptin levels with body composition and sex steroid and insulin levels in men and women. Metabolism 2000, 49(10):1278-1284.
20. Mantzoros C.S., Moschos S., Avramopoulos I., et al. Leptin concentrations in relation to body mass index and the tumor necrosis factor-alpha system in humans. J Clin Endocrinol Metab 1997, 82(10):3408-3413.
21. Banks W.A. The many lives of leptin. Peptides 2004, 25(3):331-338.
22. Kiess W., Siebler T., Englaro P., et al. Leptin as a metabolic regulator during fetal and neonatal life and in childhood and adolescence. J Pediatr Endocrinol Metab 1998, 11(4):483-496.
23. Garcia-Mayor R.V., Andrade M.A., Rios M., Lage M., Dieguez C., Casanueva F.F. Serum leptin levels in normal children: relationship to age, gender, body mass index, pituitary-gonadal hormones, and pubertal stage. J Clin Endocrinol Metab 1997, 82(9):2849-2855.
24. Kaplowitz P.B. Link between body fat and the timing of puberty. Pediatrics 2008, 121(Suppl. 3):S208-S217.
25. Karsenty G. Leptin controls bone formation through a hypothalamic relay. Recent Prog Horm Res 2001, 56:401-415.
26. Reseland J.E., Gordeladze J.O. Role of leptin in bone growth: central player or peripheral supporter?. FEBS Lett 2002, 528(1-3):40-42.
27. Fantuzzi G., Faggioni R. Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol 2000, 68(4):437-446. Review.
28. Fantuzzi G. Three questions about leptin and immunity. Brain Behav Immun 2009, 23(4):405-410.
29. Baratta M. Leptin-from a signal of adiposity to a hormonal mediator in peripheral tissues. Med Sci Monit 2002, 8(12):RA282-RA292.
30. Guerre-Millo M. Adipose tissue and adipokines: for better or worse. Diabetes Metab 2004, 30(1):13-19.
31. Somasundar P., McFadden D.W., Hileman S.M., Vona-Davis L. Leptin is a growth factor in cancer. J Surg Res 2004, 116(2):337-349.
32. Lang K., Ratke J. Leptin and adiponectin: new players in the field of tumor cell and leukocyte migration. Cell Commun Signal 2009, 23(7):27.
33. Garofalo C., Surmacz E. Leptin and cancer. J Cell Physiol 2006, 207(1):12-22.
34. Tsuchiya T., Shimizu H., Horie T., Mori M. Expression of leptin receptor in lung: leptin as a growth factor. Eur J Pharmacol 1999, 365(2-3):273-279.
35. Ribeiro R., Araújo A., Lopes C., Medeiros R. Immunoinflammatory mechanisms in lung cancer development: is leptin a mediator?. J Thorac Oncol 2007, 2(2):105-108.
36. Hoffstedt J., Eriksson P., Mottagui-Tabar S., Arner P. A polymorphism in the leptin promoter region (-2548 G/A) influences gene expression and adipose tissue secretion of leptin. Horm Metab Res 2002, 34(7):355-359.
37. Ribeiro R., Araújo A.P., Coelho A., et al. A functional polymorphism in the promoter region of leptin gene increases susceptibility for non-small cell lung cancer. Eur J Cancer 2006, 42(8):1188-1193.
38. Li Y., Geng J., Wang Y., et al. The role of leptin receptor gene polymorphisms in determining the susceptibility and prognosis of NSCLC in Chinese patients. J Cancer Res Clin Oncol 2012, 138(2):311-316.
39. Terzidis A., Sergentanis T.N., Antonopoulos G., et al. Elevated serum leptin levels: a risk factor for non-small-cell lung cancer?. Oncology 2009, 76(1):19-25.
40. Carpagnano G.E., Spanevello A., Curci C., et al. IL-2, TNF-alpha, and leptin: local versus systemic concentrations in NSCLC patients. Oncol Res 2007, 16(8):375-381.
41. Sierra-Honigmann M.R., Nath A.K., Murakami C., et al. Biological action of leptin as an angiogenic factor. Science 1998, 281(5383):1683-1686.
42. Schottenfeld D., Beebe-Dimmer J. Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin 2006, 56(2):69-83.
43. Arenberg D. Chemokines in the biology of lung cancer. J Thorac Oncol 2006, 1(4):287-288.
44. Ito N., Suzuki Y., Taniguchi Y., Ishiguro K., Nakamura H., Ohgi S. Prognostic significance of T helper 1 and 2 and T cytotoxic 1 and 2 cells in patients with non-small cell lung cancer. Anticancer Res 2005, 25(3B):2027-2031.
45. Meissner U., Hänisch C., Ostreicher I., et al. Differential regulation of leptin synthesis in rats during short-term hypoxia and short-term carbon monoxide inhalation. Endocrinology 2005, 146(1):215-220.
46. Ambrosini G., Nath A.K., Sierra-Honigmann M.R., et al. J. transcriptional activation of the human leptin gene in response to hypoxia. Involvement of hypoxia-inducible factor 1. J Biol Chem 2002, 277(37):34601-34609.
47. Anderson W.H. Acute exposure to cigarette smoke as a cause of hypoxia. Chest 1971, 59(Suppl.):33S.
48. Yang G.T., Wang D.X. Influence of cigarette smoking on the hypoxic pulmonary vasoconstriction in isolated rat lungs-the role of prostaglandins and leukotrienes. J Tongji Med Univ 1992, 12(1):6-10.
49. Kim H.J., Kim H.J., Yun J., et al. Pathophysiological role of hormones and cytokines in cancer cachexia. J Korean Med Sci 2012, 27(2):128-134.
50. Fearon K., Strasser F., Anker S.D., et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011, 12(5):489-495.
51. Dewys W.D., Begg C., Lavin P.T., et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern cooperative oncology group. Am J Med 1980, 69(4):491-497.
52. Bruera E. ABC of palliative care. Anorexia, cachexia, and nutrition. BMJ 1997, 315(7117):1219-1222.
53. Argilés J.M., Busquets S., Toledo M., López-Soriano F.J. The role of cytokines in cancer cachexia. Curr Opin Support Palliat Care 2009, 3(4):263-268.
54. Simons J.P., Schols A.M., Campfield L.A., Wouters E.F., Saris W.H. Plasma concentration of total leptin and human lung-cancer-associated cachexia. Clin Sci (Lond) 1997, 93(3):273-277.
55. Alemán M.R., Santolaria F., Batista N., et al. Leptin role in advanced lung cancer. A mediator of the acute phase response or a marker of the status of nutrition?. Cytokine 2002, 19(1):21-26.
56. Jamieson N.B., Brown D.J., Michael Wallace A., McMillan D. Adiponectin and the systemic inflammatory response in weight-losing patients with non-small cell lung cancer. Cytokine 2004, 27(2-3):90-92.
57. Tas F., Duranyildiz D., Argon A., et al. Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer. Med Oncol 2005, 22(4):353-358.
58. Weryńska B., Kosacka M., Gołecki M., Jankowska R. Leptin serum levels in cachectic and non-cachectic lung cancer patients. Pneumonol Alergol Pol 2009, 77(6):500-506.
59. Smiechowska J., Utech A., Taffet G., Hayes T., Marcelli M., Garcia J.M. Adipokines in patients with cancer anorexia and cachexia. J Investig Med 2010, 58(3):554-559.
60. Gulen S.T., Karadag F., Karul A., et al. Adipokines and Systemic Inflammation in Weight-Losing Lung Cancer Patients. Lung 2012, 190(3):327-332.
61. Mantovani G., Macciò A., Madeddu C., et al. Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites. J Mol Med (Berl) 2001, 79(7):406-414.
62. Karapanagiotou E.M., Tsochatzis E.A., Dilana K.D., Tourkantonis I., Gratsias I., Syrigos K.N. The significance of leptin, adiponectin, and resistin serum levels in non-small cell lung cancer (NSCLC). Lung Cancer 2008, 61(3):391-397.
63. Meek C.L., Wallace A.M., Forrest L.M., McMillan D.C. The relationship between the insulin-like growth factor-1 axis, weight loss, an inflammation-based score and survival in patients with inoperable non-small cell lung cancer. Clin Nutr 2010, 29(2):206-209.
64. Gioulbasanis I., Georgoulias P., Vlachostergios P.J., et al. Mini nutritional assessment (MNA) and biochemical markers of cachexia in metastatic lung cancer patients: interrelations and associations with prognosis. Lung Cancer 2011, 74(3):516-520.
65. Xu Y.J., Shao Y.F., Zhao X., Geng Y.T., Wang K., Yin Y.M. Expression and clinical significance of leptin, the functional receptor of leptin (OB-Rb) and HER-2 in non-small-cell lung cancer: a retrospective analysis. J Cancer Res Clin Oncol 2011, 137(12):1841-1848.
66. Maeda K., Okubo K., Shimomura I., Funahashi T., Matsuzawa Y., Matsubara K. CDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose most abundant gene transcript 1). Biochem Biophys Res Commun 1996, 221(2):286-289.
67. Hu E., Liang P., Spiegelman B.M. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996, 271(18):10697-10703.
68. Yamauchi T., Kamon J., Ito Y., et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003, 423(6941):762-769.
69. Kadowaki T., Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005, 26(3):439-451.
70. Hug C., Wang J., Ahmad N.S., Bogan J.S., Tsao T.S., Lodish H.F. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci USA 2004, 101(28):10308-10313.
71. Koerner A., Kratzsch J., Kiess W. Adipocytokines: leptin-the classical, resistin-the controversical, adiponectin-the promising, and more to come. Best Pract Res Clin Endocrinol Metab 2005, 19(4):525-546.
72. Whitehead J.P., Richards A.A., Hickman I.J., Macdonald G.A., Prins J.B. Adiponectin-a key adipokine in the metabolic syndrome. Diabetes Obes Metab 2006, 8(3):264-280.
73. Matsuzawa Y. Adiponectin: identification, physiology and clinical relevance in metabolic and vascular disease. Atheroscler Suppl 2005, 6(2):7-14.
74. De Las Heras J., Lee S., Bacha F., Tfayli H., Arslanian S. Cross-sectional association between blood pressure, in vivo insulin sensitivity and adiponectin in overweight adolescents. Horm Res Paediatr 2011, 76(6):379-385.
75. Kelesidis I., Kelesidis T., Mantzoros C.S. Adiponectin and cancer: a systematic review. Br J Cancer 2006, 94(9):1221-1225.
76. Wang Y., Lam K.S., Xu J.Y., et al. Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem 2005, 280:18341-18347.
77. Bråkenhielm E., Veitonmäki N., Cao R., et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA 2004, 101(8):2476-2481.
78. Ouchi N., Kihara S., Arita Y., et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999, 100:2473-2476.
79. Yokota T., Oritani K., Takahashi I., et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000, 96:1723-1732.
80. Petridou E.T., Mitsiades N., Gialamas S., et al. Circulating adiponectin levels and expression of adiponectin receptors in relation to lung cancer: two case-control studies. Oncology 2007, 73(3-4):261-269.
81. Hara K., Boutin P., Mori Y., et al. Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes 2002, 51(2):536-540.
82. Kaklamani V.G., Sadim M., Hsi A., et al. Variants of the adiponectin and adiponectin receptor 1 genes and breast cancer risk. Cancer Res 2008, 68(9):3178-3184.
83. Beebe-Dimmer J.L., Zuhlke K.A., Ray A.M., Lange E.M., Cooney K.A. Genetic variation in adiponectin (ADIPOQ) and the type 1 receptor (ADIPOR1), obesity and prostate cancer in African Americans. Prostate Cancer Prostatic Dis 2010, 13(4):362-368.
84. Kaklamani V.G., Wisinski K.B., Sadim M., et al. Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer risk. Source JAMA 2008, 300(13):1523-1531.
85. Cui E., Deng A., Wang X., et al. The role of adiponectin (ADIPOQ) gene polymorphisms in the susceptibility and prognosis of non-small cell lung cancer. Biochem Cell Biol 2011, 89(3):308-313. 10.1139/O11-005.
86. Govindarajan R., Ratnasinghe L., Simmons D.L., et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 2007, 25(12):1476-1481.
87. Ferrara A., Lewis J.D., Quesenberry C.P., et al. Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care 2011, 34(4):923-929.
88. Holcomb I.N., Kabakoff R.C., Chan B., et al. FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J 2000, 19(15):4046-4055.
89. Steppan C.M., Lazar M.A. The current biology of resistin. J Intern Med 2004, 255(4):439-447.
90. Patel L., Buckels A.C., Kinghorn I.J., et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003, 300(2):472-476.
91. Steppan C.M., Bailey S.T., Bhat S., et al. The hormone resistin links obesity to diabetes. Nature 2001, 409(6818):307-312.
92. Janke J., Engeli S., Gorzelniak K., Luft F.C., Sharma A.M. Resistin gene expression in human adipocytes is not related to insulin resistance. Obes Res 2002, 10(1):1-5.
93. Filková M., Haluzík M., Gay S., Senolt L. The role of resistin as a regulator of inflammation: Implications for various human pathologies. Clin Immunol 2009, 133(2):157-1570. Epub 2009 Sep 8.
94. Kang J.H., Yu B.Y., Youn D.S. Relationship of serum adiponectin and resistin levels with breast cancer risk. J Korean Med Sci 2007, 22(1):117-121.
95. Pamuk G.E., Demir M., Harmandar F., Yesil Y., Vural Turgut B. Leptin and resistin levels in serum of patients with hematologic malignancies: correlation with clinical characteristics. Exp Oncol 2006, 28(3):241-244.
96. Mu H., Ohashi R., Yan S., et al. Adipokine resistin promotes in vitro angiogenesis of human endothelial cells. Cardiovasc Res 2006, 70(1):146-157.
97. Bozaoglu K., Bolton K., McMillan J., et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 2007, 148(10):4687-4694.
98. MacDougald O.A., Burant C.F. The rapidly expanding family of adipokines. Cell Metab 2007, 6(3):159-161.
99. Bondue B., Wittamer V., Parmentier M. Chemerin and its receptors in leukocyte trafficking, inflammation and metabolism. Cytokine Growth Factor Rev 2011, 22(5-6):331-338.
100. Qu X., Han L., Wang S., et al. Detection of chemerin and it's clinical significance in peripheral blood of patients with lung cancer. Zhongguo Fei Ai Za Zhi 2009, 12(11):1174-1177.
101. Sommer G., Garten A., Petzold S., et al. Visfatin/PBEF/Nampt: structure, regulation and potential function of a novel adipokine. Clin Sci (Lond) 2008, 115(1):13-23.
102. Fukuhara A., Matsuda M., Nishizawa M., et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005, 307(5708):426-430.
103. Fukuhara A., Matsuda M., Nishizawa M., et al. Retraction Sci 2007, 318(5850):565.
104. Moschen A.R., Kaser A., Enrich B., et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007, 178(3):1748-1758.
105. Bi T.Q., Che X.M. Nampt/PBEF/visfatin and cancer. Cancer Biol Ther 2010, 10(2):119-125.
106. Okumura S., Sasaki T., Minami Y., Ohsaki Y. Nicotinamide phosphoribosyltransferase: a potent therapeutic target in non-small cell lung cancer with epidermal growth factor receptor-gene mutation. J Thorac Oncol 2012, 7(1):49-56.
107. Heber D., Byerly L.O., Chlebowski R.T. Metabolic abnormalities in the cancer patient. Cancer 1985, 55(1 Suppl.):225-229.
108. Yoshikawa T., Noguchi Y., Doi C., et al. Insulin resistance in patients with cancer: relationships with tumor site, tumor stage, body-weight loss, acute phase response, and energy expenditure. Nutrition 2001, 17(7-8):590-593.
109. Leij-Halfwerk S., Dagnelie P.C., van Den Berg J.W., et al. Weight loss and elevated gluconeogenesis from alanine in lung cancer patients. Am J Clin Nutr 2000, 71(2):583-589.
110. Yang Y., Dong J., Sun K., et al. Obesity and incidence of lung cancer: a meta-analysis. Int J Cancer 2013, 132(5):1162-1169.
111. Elinav E., Niv-Spector L., Katz M., et al. Pegylated leptin antagonist is a potent orexigenic agent: preparation and mechanism of activity. Endocrinology 2009, 150(7):3083-3091.